This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond
This week, we will discuss hopefully the final story of intensive BP lowering. BPROAD is a larger version of ACCORD without the glycemic control arm. Dive in.
Its that time of year again! Jade Teakell is leading team #UrineItToWinIt for #HCWvsHunger 2024. Read more.
This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.
The Filtrate welcome Drs. Anna Burgner and George Bakris to discuss the breakthrough clinical trial FIDELIO and the non-steroidal aldosteropne antagonist, finerenone.
The Filtrate welcome Drs. Katherine Tuttle and Ian de Boer to discuss the first KDIGO diabetic kidney disease guideline.
